Literature DB >> 29941675

The inverse relationship between prostate specific antigen (PSA) and obesity.

Adel T Aref1,2, Andrew D Vincent1,2, Michael E O'Callaghan1,3,4,5, Sean A Martin1,2, Peter D Sutherland6, Andrew J Hoy7, Lisa M Butler8,2, Gary A Wittert8,2.   

Abstract

Obese men have lower serum prostate-specific antigen (PSA) than comparably aged lean men, but the underlying mechanism remains unclear. The aim of this study was to determine the effect of obesity on PSA and the potential contributing mechanisms. A cohort of 1195 men aged 35 years and over at recruitment, with demographic, anthropometric (BMI, waist circumference (WC)) and serum hormone (serum testosterone, estradiol (E2)) PSA and hematology assessments obtained over two waves was assessed. Men with a history of prostate cancer or missing PSA were excluded, leaving 970 men for the final analysis. Mixed-effects regressions and mediation analyses adjusting for hormonal and volumetric factors explore the potential mechanisms relating obesity to PSA. After adjusting for age, PSA levels were lower in men with greater WC (P = 0.001). In a multivariable model including WC, age, E2/testosterone and PlasV as predictors, no statistically significant associations were observed between with PSA and either WC (P = 0.36) or PlasV (P = 0.49), while strong associations were observed with both E2/testosterone (P < 0.001) and age (P < 0.001). In the mediation analyses with PlasV as the mediator, the average causal mediation effect (ACME) explained roughly 20% of the total effect of WC on PSA (P = 0.31), while when E2/testosterone is a mediator, the ACME explained roughly 50% of the effect (P < 0.001). Our findings indicate that lower PSA levels in obese men, as compared to normal weight men, can be explained both by hormonal changes (elevated E2/testosterone ratio) and hemodilution. Hormonal factors therefore represent a substantial but underappreciated mediating pathway.
© 2018 Society for Endocrinology.

Entities:  

Keywords:  PSA; estradiol; hemodilution; obesity; prostate cancer; prostate cancer screening; testosterone

Mesh:

Substances:

Year:  2018        PMID: 29941675     DOI: 10.1530/ERC-17-0438

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  5 in total

1.  Obesity at Diagnosis and Prostate Cancer Prognosis and Recurrence Risk Following Primary Treatment by Radical Prostatectomy.

Authors:  Crystal S Langlais; Janet E Cowan; John Neuhaus; Stacey A Kenfield; Erin L Van Blarigan; Jeanette M Broering; Matthew R Cooperberg; Peter Carroll; June M Chan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-08-28       Impact factor: 4.254

2.  Association between serum prostate-specific antigen level and diabetes, obesity, hypertension, and the laboratory parameters related to glucose tolerance, hepatic function, and lipid profile: implications for modification of prostate-specific antigen threshold.

Authors:  Minoru Kobayashi; Tomoya Mizuno; Hideo Yuki; Tsunehito Kambara; Hironori Betsunoh; Akinori Nukui; Hideyuki Abe; Yoshitatsu Fukabori; Masahiro Yashi; Takao Kamai
Journal:  Int J Clin Oncol       Date:  2019-08-22       Impact factor: 3.402

3.  PSA and obesity among men with localized prostate cancer: results of the ANDROCAN study.

Authors:  Matthias E Meunier; Yann Neuzillet; Jean-François Dreyfus; Marc Schneider; Morgan Rouprêt; Xavier Cathelineau; Jean-Pierre Raynaud; Thierry Lebret; Henry Botto
Journal:  World J Urol       Date:  2021-02-01       Impact factor: 4.226

4.  Development and validation of a multi-parameter nomogram for predicting prostate cancer: a retrospective analysis from Handan Central Hospital in China.

Authors:  Libin Nan; Kai Guo; Mingmin Li; Qi Wu; Shaojun Huo
Journal:  PeerJ       Date:  2022-03-02       Impact factor: 2.984

5.  Association between serum prostate-specific antigen concentrations and the risk of developing type 2 diabetes mellitus in Chinese men: A cohort study.

Authors:  Shao-Fen Huang; Ying-Lin Yu; Yun-Feng Cui; Yan-Mei Lou; Min-Qi Liao; Chang-Yi Wang; Shan Xu; Hong-En Chen; Xu-Ping Gao; Shu-Hong Dai; Xiao-Lin Peng; Dan Zhao; Li Wang; Zhao Ping; Fang-Fang Zeng
Journal:  J Diabetes Investig       Date:  2021-03-04       Impact factor: 4.232

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.